Legislation
- Title
- Pharmacists – Required Notification and Authorized Substitution – Lower–Cost Drug or Device Product
- Sponsored by
- Delegates Shetty, Bagnall, Barron, Belcastro, Bhandari, Carr, Charles, Chisholm, Cullison, Hill, Johnson, Kelly, Kerr, Kipke, Krebs, R. Lewis, Morgan, Pena-Melnyk, Pendergrass, Reilly, Rosenberg, Saab, Sample-Hughes, Szeliga, and K. Young
- Status
- In the Senate - Reassigned to Education, Health, and Environmental Affairs
- Analysis
- Fiscal and Policy Note (Revised)
Synopsis
Requiring a pharmacist, or the pharmacist's designee who is under certain supervision, to inform a certain consumer of the availability of certain therapeutically equivalent drugs and the cost difference between the therapeutically equivalent drug and a certain prescribed drug; altering the cost difference of which a pharmacist, or the pharmacist's designee is required to inform a retail consumer under certain circumstances; requiring that a certain determination be based on a consumer's prescription benefit and formulary; etc.
Committees
Committee Testimony
Details
Bill File Type: Regular
Effective Date(s): October 1, 2020
History
Toggle History Dropdown
File Code
Toggle Filecode Dropdown
Subjects
Toggle Subjects Dropdown
Statutes
Toggle Statutes Dropdown
(
12-504 )
Last Updated: 9/22/2020 2:20 PM